Nectar Lifesciences Limited — Dividend/Bonus, 15-01-2026: Post Buyback Public Announcement

Nectar Lifesciences successfully wrapped up its tender offer buyback, repurchasing 3 crore equity shares at ₹27 apiece for a total of ₹81 Cr. The tendering window closed January 06, 2026, with settlements finalized by January 13, 2026. These shares are currently being extinguished, a move that will effectively reduce the company's outstanding equity capital. Key takeaway for investors: lower share count incoming.